Global Markets for Infectious Disease Treatments

Published - Mar 2018| Analyst - Megha Joshi-Sood| Code - PHM061D
Global Markets for Infectious Disease Treatments
Single User License: $5500 Member Price: FREE

Report Highlights

The global market for infectious disease treatments totaled $64.8 billion in 2017. The market should total $99 billion by 2022, growing at a compound annual growth rate (CAGR) of 8.9% from 2017 to 2022.

Report Includes

  • 84 data tables and 23 additional tables
  • An overview of the global market for infectious disease treatments, with a focus on the growth in demand for newer pharmaceutical treatments, vaccines, and environmental products
  • Analyses of global market trends with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Discussion of the increasing concerns regarding antibiotic-resistant organisms and their sometimes-fatal effects on humans
  • Examination of technological developments, future trends, and emerging opportunities
  • Assessments of the current state of infectious diseases on a global basis, broken down by type of disease (i.e., bacterial, viral, parasitic, and fungal) and appropriate treatments, both current and anticipated, and by region
  • Patent analyses
  • Company profiles of major players in the market, including Alere (now Abbott), Novartis, Roche Diagnostics, Sanofi Pasteur and Siemens Healthineers

Report Scope

The report focuses on newer drugs and innovations in chemical compounds, vaccines and biologicals and diagnostic kits, recently launched or in development. Specifically excluded from the scope of research are vector or mosquito control approaches, strategies and products; drugs used for symptomatic treatment and not for the elimination of the virus from the host; and details on manufacturers and suppliers of non-branded generics.

BCC Research has categorized the markets based on regions defined by the WHO since it is the primary organization mapping disease prevalence, assisting with access to medicine and enabling partnerships in a large number of infectious diseases. Regions include Africa, Americas, South-East Asia, Europe, Eastern Mediterranean and Western Pacific. These cover all the WHO participating countries, which are described in detail in the subsequent section.

Analyst Credentials

Ms. Joshi has a master’s degree in biotechnology from the Indian Institute of Technology (I.I.T), Mumbai, and a diploma in management consulting from the Consultancy Development Centre, DSIR, Ministry of Science and Technology, India. She has eight years of research experience in competitive intelligence, technology strategy and market analysis in the pharmaceuticals, biotechnology and agrochemical industries. Her latest report for BCC Research, PHM180A Global Markets for Neglected Tropical Disease Treatments, was published in June 2017.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - Jan-2016| Analyst - Peggy Lehr| Code - PHM061C

Report Highlights

The global market for infectious disease diagnostic, vaccine, and treatment products reached $108.4 billion in 2015. The market should reach $126.2 billion in 2016 and $183.2 billion in 2021, demonstrating a compound annual growth rate (CAGR) of 7.7% from 2016 to 2021.

Report Includes

  • An overview of the global market for infectious disease treatments, with a focus on the growth in demand for newer pharmaceutical treatments, vaccines, and environmental products.
  • Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2021.
  • Discussion of the increasing concern regarding antibiotic-resistant organisms and their sometimes-fatal effects on humans.
  • Examination of technological developments, future trends, and emerging opportunities.
  • Assessments of the current state of infectious diseases on a global basis, broken down by type of disease (i.e., bacterial, viral, parasitic, and fungal) and appropriate treatments, both current and anticipated, and by geographic region.
  • A relevant patent analysis.
  • Profiles of major players in the field of infectious disease treatments.

Published - May-2013| Analyst - Peggy Lehr| Code - PHM061B

Report Highlights

The global market for infectious disease diagnostic, vaccine and pharmaceutical products was $59.2 billion in 2011 and $66.4 billion in 2012.  Market growth looks promising, the overall market value for 2017 is projected to be $96.8 billion after increasing at a compound annual growth rate (CAGR) of 7.8%.

Report Includes

  • An overview of the global market for infectious disease treatments, with a focus on the growth in demand for newer pharmaceutical treatments, vaccines, and environmental products
  • Analyses of global market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017
  • Discussion of the increasing concern regarding antibiotic-resistant organisms and their sometimes-fatal effects on humans
  • Examination of technological developments, future trends, and emerging opportunities
  • Assessments of the current state of infectious diseases on a global basis, broken down by type of disease (i.e., bacterial, viral, parasitic, and fungal) and appropriate treatments, both current and anticipated, and by geographic region
  • Patent analysis
  • Comprehensive company profiles of major players.

Published - Apr-2010| Analyst - Peggy Lehr| Code - PHM061A

Report Highlights

  • The global market for infectious disease treatments was valued at $90.4 billion in 2009. This market is expected to increase at a compound annual growth rate (CAGR) of 8.8% to reach $138 billion in 2014.
  • The largest market share belongs to antibiotic treatments for bacterial and fungal diseases at 53% of the total infectious disease treatment market.  Fungal disease treatments will experience a slightly higher compound annual growth rate (CAGR) of 6.2%, from $4.6 billion in 2009 to $6.2 billion in 2014.
  • Viral disease treatments will have the fastest compound annual growth rate (CAGR) of 12.1%, increasing from nearly $45 billion in 2009 to $79 billion in 2014.
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report